Peculiarities of Seroprovalence to SARS-CoV-2 in the Population of the Middle and Southern Urals in the Early Period of the COVID-19 Pandemic

Relevance. At the end of 2019, the world was confronted with a novel coronavirus (SARS-CoV-2), In January 2020, WHO declared an epidemic related to SARS-CoV-2, a health emergency of international importance, and in March characterized the spread of the world. diseases like a pandemic.

Purpose of the study. Conduct a comparative analysis of the seroprevalence of the population of the Sverdlovsk and Chelyabinsk regions – the largest administrative territorial entities of the Middle and Southern Urals – against the backdrop of the COVID-19 pandemic.

Materials and methods. The work was carried out under the program of the first stage of assessing the seroprevalence of the population of the Russian Federation according to a unified methodology developed by Rospotrebnadzor of the Russian Federation with the participation of the Saint Petersburg Pasteur Institute. The selection of participants was carried out by the method of questioning and randomization. The presence of antibodies to the SARS-CoV-2 nucleocapsid was determined in blood serum by the enzyme immunoassay.

Results. Comparative analysis of the results showed that the incidence rate of COVID-19 in the Chelyabinsk region was consistently lower, and the seroprevalence at the first stage of the study was statistically significantly higher (p <0/05) than in the Sverdlovsk region. It was found that the incidence in both regions had a direct correlation with population density (r = 0.59; p <0.05). There were no differences between the compared areas in terms of seroprevalence among convalescents, people who had contact with COVID-19 patients, and asymptomatic volunteers with a positive PCR test. When analyzing seroprevalent volunteers in both regions, it was shown that the number of asymptomatic individuals varied within 94.4 ± 1.2% – 95.0 ± 0.95%. These data indicate that the majority of volunteers tolerated COVID-19 asymptomatically.

Conclusions. A comparative study showed a statistically significant predominance of seroprevalence among the population of the Chelyabinsk region. It was found that an increase in seroprevalence at the population level was accompanied by a decrease in morbidity. Shown is a direct relationship between population density and the incidence rate. More than 90% of seropositive individuals in the compared areas showed asymptomatic course of coronavirus infection.

1. Novel Coronavirus(2019-nCoV) Situation Report – 11. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200131-sitrep-11-ncov.pdf?sfvrsn=de7c0f7_2.

2. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020. Available at: https://www.who.int/director-general/speeches/detail/whodirector-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.

3. Morens, D.M., Fauci, A.S., Emerging Pandemic Diseases: How We Got To COVID-19. Cell. 2020; 183(3):837. doi: 10.1016/j.cell.2020.10.022.

4. Xu X., Chen, P., Wang, J., et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. China Life Sci. 2020; 63:457–460. doi. 10.1007/s11427-020-1637-5.

5. Bchetnia M., Girard C., Duchaine C., Laprise C. The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status. J Inf. Public Health. 2020; 13(11):1601–1610. doi: 10.1016/j.jiph.2020.07.011.

6. Clemente-Suárez V.J., Hormeño-Holgado A., Jiménez M., et al.Dynamics of population immunity due to the herd effect in the COVID-19 pandemic. Vaccines (Basel). 2020; 8(2):E236. doi: 10.3390/vaccines8020236.

7. Liu L., Wei Q., Lin Q., et al. Anti–spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight. 201; 4(4):e123158. doi: 10.1172/jci.insight.123158.

8. El-Sayed A., Aleya L., Kamel M. COVID-19: a new emerging respiratory disease from the neurological perspective Environ Sci Pollut Res Int. 2021; 15: 1–15. doi: 10.1007/s11356-021-12969-9.

9. Ortiz-Prado E., Simbaña-Rivera K., Gómez- Barreno L., et al. Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review. Diagn Microbiol Infect Dis. 2020; 98(1):115094. doi: 10.1016/j.diagmicrobio.2020.115094.

10. Popova A.Yu., Ezhlova E.B., Melnikova A.A., et al. Distribution of SARS-CоV-2 seroprevalence among residents of the Tyumen Region during the COVID-19 epidemic period. Journal of microbiology, epidemiology and immunobiology = Zhurnal mikrobiologii, èpidemiologii I immunobiologii. 2020; 97(5): 392–400. (In Russian) doi: doi: 10.36233/0372-9311-2020-97-5-1.

11. Popova A.Yu., Ezhlova E.B., Mel’nikova A.A., et al. Herd Immunity to SARS-CoV-2 among the Population in Saint-Petersburg during the COVID-19 Epidemic. Problemy Osobo Opasnykh Infektsii [Problems of Particularly Dangerous Infections]. 2020; 3:124–130. (In Russian). doi: 10.21055/0370-1069-2020-3-124-130.

12. Popova A.Yu., Ezhlova E.B., Mel’nikova A.A., Assessment of the Herd Immunity to SARS-CoV-2 among the Population of the Leningrad Region during the COVID-19 Epidemic. Problemy Osobo Opasnykh Infektsii [Problems of Particularly Dangerous Infections]. 2020; 3:114–123. (In Russian). doi: 10.21055/0370-1069-2020-3-114-123.

13. Newcombe R.G. Two-sided confidence intervals for the single proportion: comparison of seven methods. Statistics in Medicine, 1998, vol. 17, pp. 857–887. doi: 10.1002/(sici)1097-0258(19980430)17:8<857::aid-sim777>3.0.co;2-e.

14. Popova A.Yu., Andreeva E.E., Babura E.A., et al. Features of developing SARS-CoV-2 nucleocapsid protein population-based seroprevalence during the firstwave of the COVID-19 epidemic in the Russian Federation. Russian Journal of Infection and Immunity=Infektsya i immunitet. 2021; 11(2):297–323. doi:10.15789/2220-7619-FOD-1684.

15. Rocklöv J, Sjödin H High population densities catalyze the spread of COVID-19.J Travel Med. 2020: taaa038. doi: 10.1093/jtm/taaa038.

16. Sanche S., Lin Y.T., Xu C., et al. High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2. Emerg Infect Dis. 2020; 26(7):1470–1477. doi: 10.3201/eid2607.200282.

17. Walsh K.A., Jordan K., Clyne B., et al. SARS-CoV-2 detection, viral load and infectivity over the course of an infection. J Infect. 2020; 81(3):357–371. doi: 10.1016/j.jinf.2020.06.067.

18. Mason R.J. Pathogenesis of COVID-19 from a cell biologic perspective Eur Respir J. 2020; 55(4):2000607. doi: 10.1183/13993003.00607-2020.

19. Chou R., Dana T., Jungbauer R., et al. Masks for Prevention of Respiratory Virus Infections, Including SARS-CoV-2, in Health Care and Community Settings: A Living Rapid Review. Ann Intern Med. 2020; 173(7):542–555. doi: 10.7326/M20-3213

20. Li Y., Liang M., Gao L., et al. Face masks to prevent transmission of COVID-19: A systematic review and meta-analysis. Am J Infect Control. 2020; (in press). doi: 1016/j.ajic.2020.12.007.

21. Mizumoto K., Kagaya K., Zarebski A., Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020 Euro Surveill. 2020; 25(10): 2000180. doi: 10.2807/1560-7917.ES.2020.25.10.2000180.

22. Zhao D., Wang M., Wang M., et al. Asymptomatic infection by SARS-CoV-2 in healthcare workers: A study in a large teaching hospital in Wuhan, China. Int J Infect Dis. 2020; 99:219–225. doi: 10.1016/j.ijid.2020.07.082.

23. Loos C., Atyeo C., Fischinger S., et al. Evolution of Early SARS-CoV-2 and Cross-Coronavirus Immunity. mSphere. 2020; 5(5): e00622-20. doi: 10.1128/mSphere.00622-20.

24. Buitrago-Garcia D., Egli-Gany D., Counotte M.J., et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. PLoS Med. 2020; 17(9):e1003346. doi: 10.1371/journal.pmed.1003346.

25. Oran D.P., Topol E.J. Prevalence of Asymptomatic SARS-CoV-2 Infection: A Narrative Review. Ann Intern Med. 2020; 173(5):362–367. doi: 10.7326/M20-3012.

26. Lee S., Meyler P., Mozel M., Tauh T., Merchant R.Asymptomatic carriage and transmission of SARS-CoV-2: What do we know? Can J Anaesth. 2020; 67(10):1424–1430. doi: 10.1007/s12630-020-01729-x.

27. Yu X. Modeling return of the epidemic: Impact of population structure, asymptomatic infection, case importation and personal contacts/ Travel Med Infect Dis. 2020; 37:101858. doi: 10.1016/j.tmaid.2020.101858.

28. Randolph H. E., Barreiro L. B. Herd Immunity: Understanding COVID-19 Immunity. 2020, 52(5): 737–741. doi: 10.1016/j.immuni.2020.04.012.